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Chondroitin sulfate proteoglycans (CSPGs), up-regulated in and around the lesion after traumatic spinal cord
injury (SCI), are key extracellular matrix inhibitory molecules that limit axon growth and consequent recovery of
function. CSPG-mediated inhibition occurs via interactions with axonal receptors, including leukocyte common
antigen- related (LAR) phosphatase. We tested the effects of a novel LAR inhibitory peptide in rats after hemi
section at cervical level 2, a SCI model in which bulbospinal inspiratory neural circuitry originating in the
medullary rostral ventral respiratory group (rVRG) becomes disconnected from phrenic motor neuron (PhMN)
targets in cervical spinal cord, resulting in persistent partial-to-complete diaphragm paralysis. LAR peptide was
delivered by a soaked gelfoam, which was placed directly over the injury site immediately after C2 hemisection
and replaced at 1 week post-injury. Axotomized rVRG axons originating in ipsilateral medulla or spared rVRG
fibers originating in contralateral medulla were separately assessed by anterograde tracing via AAV2-mCherry
injection into rVRG. At 8 weeks post-hemisection, LAR peptide significantly improved ipsilateral hemi
diaphragm function, as assessed in vivo with electromyography recordings. LAR peptide promoted robust
regeneration of ipsilateral-originating rVRG axons into and through the lesion site and into intact caudal spinal
cord to reach PhMNs located at C3-C5 levels. Furthermore, regenerating rVRG axons re-established putative
monosynaptic connections with their PhMNs targets. In addition, LAR peptide stimulated robust sprouting of
both modulatory serotonergic axons and contralateral-originating rVRG fibers within the PhMN pool ipsilateral/
caudal to the hemisection. Our study demonstrates that targeting LAR-based axon growth inhibition promotes
multiple forms of respiratory neural circuit plasticity and provides a new peptide-based therapeutic strategy to
ameliorate the devastating respiratory consequences of SCI.

Abbreviations: AAV2, Adeno-associated virus serotype 2; C2 (3, 4, 5, etc.), Cervical spinal cord level 2 (3, 4, 5, etc.); CMAP, Compound muscle action potential;
CNS, Central nervous system; CSPG, Chondroitin sulfate proteoglycan; CTB, Cholera toxin subunit B; ECM, Extracellular matrix; EMG, Electromyography; GAG,
Glycosaminoglycan; GFAP, Glial fibrillary acidic protein; LAR, Leukocyte common antigen-related; NMJ, Neuromuscular junction; PhMN, Phrenic motor neuron;
RPTP, Receptor protein tyrosine phosphatase; rVRG, Rostral ventral respiratory group; SCI, Spinal cord injury; VGLUT2, Vesicular glutamate transporter 2; 5-HT, 5hydroxytryptamine.
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1. Introduction

steric hindrance of adhesion molecules that are growth promoting, the
transmembrane protein tyrosine phosphatase-sigma (PTPσ) (Fry et al.,
2010; Shen et al., 2009) and related phosphatase leukocyte common
antigen-related (LAR) (Fisher et al., 2011; Wong et al., 1993; Yang et al.,
1999) have been identified as the axonal receptors for the inhibitory
actions of CSPGs. In addition to PTPσ and LAR, CSPGs can exert axon
growth inhibitory effects via signaling through Nogo receptors 1 and 3
(Dickendesher et al., 2012). LAR and PTPσ belong to the type IIa/LAR
subfamily of receptor protein tyrosine phosphatases (RPTP), which in
cludes the three vertebrate members LAR, PTPδ and PTPσ (Tonks,
2006). Structurally, LAR RPTP contains an Ig-like domain that binds
CSPGs, an extracellular fifth fibronectin type III domain, and an intra
cellular wedge-shaped helix-loop-helix (Xie et al., 2020). The large
extracellular regions of LAR RPTP can interact with additional extra
cellular ligands besides proteoglycans (e.g. liprin-α, netrin-G ligand-3,
TrkB) (Han et al., 2016; Takahashi and Craig, 2013), thereby mediating
proteoglycan-regulated processes such as axon guidance and excitatory
presynaptic and postsynaptic assembly (Fisher et al., 2011; Shen et al.,
2009). CSPGs bind to LAR RPTPs on the axon membrane to regulate a
number of intracellular transduction pathways. This signaling can
include stimulation of the RhoA kinase pathway and inactivation Akt
and Erk pathways (Fisher et al., 2011) to restrict neurite outgrowth
(Fisher et al., 2011; Lang et al., 2015; Xu et al., 2015). Deletion of LAR in
knockout mice significantly overcomes CSPG-mediated neurite growth
inhibition in neuronal culture (Fisher et al., 2011). Similarly, systemic
treatment with LAR-targeting inhibitory peptides that block LAR activ
ity in mice with thoracic transection SCI induces significant growth of
descending serotonergic axons and also promotes locomotor functional
recovery (Fisher et al., 2011). Additionally, inhibition of LAR promotes
oligodendrogenesis from endogenous progenitor cells, attenuates cas
pase 3-mediated cell death of mature oligodendrocytes, and preserves
myelin after SCI (Dyck et al., 2018). Based on this body of work, LAR
RPTP is a promising target for interventions that block the effects of
CSPGs and provides an opportunity to enhance axon growth after CNS
injury.
Respiratory dysfunction is an extremely debilitating outcome of SCI
that results in part from disruption of bulbospinal circuitry that controls
the diaphragm, a primary muscle of inspiration (Warren et al., 2014).
Phrenic motor neurons (PhMNs) located at cervical spinal cord level 3
(C3)-5 (C5) innervate the ipsilateral diaphragm (Lane et al., 2009).
These PhMNs receive primarily monosynaptic excitatory drive from
rostral ventral respiratory group (rVRG) neurons located in medulla
(Zimmer et al., 2007). PhMNs are also connected with rVRG neurons
through poly-synaptic circuits involving pre-phrenic interneurons of
cervical spinal cord (Lane et al., 2008b; Zholudeva et al., 2017). Cervical
SCI damages this descending bulbospinal axon input to the PhMNs. As
little growth of damaged axons occurs after SCI, PhMNs remain dener
vated from their rVRG input, resulting in persistent partial-to-complete
diaphragm paralysis.
In a rat model of C2 hemisection-type SCI (Urban et al., 2019a; Urban
et al., 2019b; Urban et al., 2018), we explored mechanisms of rVRGPhMN-diaphragm circuit plasticity that can drive recovery of dia
phragm function in response to manipulating axon growth inhibition.
Specifically, we administered a novel LAR-targeting sequence-selective
inhibitory peptide (abbreviated as LAR peptide) to the injured cervical
spinal cord and assessed effects on diaphragm function using in vivo
electrophysiological assays. In addition, we examined neuroanatomical
effects of LAR inhibition on respiratory neural circuitry using antero
grade and retrograde tracing approaches to quantitatively assess
regeneration of injured rVRG axons, sprouting of spared rVRG fibers,
and monosynaptic connectivity of these rVRG axon populations with
PhMN targets located caudal to the lesion site. Furthermore, we took
advantage of the observed animal-to-animal variability in LAR peptideinduced functional effects and axon growth responses to perform cor
relation analyses to explore mechanisms of rVRG-PhMN-diaphragm
circuit plasticity responsible for driving recovery of diaphragm function.

Following traumatic spinal cord injury (SCI), functional deficits vary
depending on the anatomical location, type and severity of the insult, as
well as on the specific neural circuits affected (Ahuja et al., 2017).
Approximately half of all SCI cases are located within the cervical spinal
cord, with many of these individuals suffering from debilitating and
persistent respiratory deficits and relying on mechanical ventilation for
the remainder of their lives (Lane et al., 2008a). Despite surgical inter
vention (e.g. vertebral bone stabilization), supportive and rehabilitation
interventions, individuals affected by SCI carry a life-long risk for
complications arising from motor, sensory and autonomic deficits. The
limited ability of the injured spinal cord to repair itself remains a major
barrier to achieving meaningful recovery of function after SCI. In
particular, the severed axonal projections of damaged neurons are not
capable of mounting a robust regenerative response after SCI, resulting
in permanent disconnection of the neural circuits responsible for
mediating various behaviors.
Understanding the mechanisms that can drive a successful axon
regrowth process after central nervous system (CNS) injury is critical to
develop methods to therapeutically promote recovery of function in SCI
and other neurological diseases. Without any intervention, spontaneous
axon growth is extremely limited after SCI due in part to neuronalextrinsic factors present in the injured CNS, including reactive scarring
(Burda and Sofroniew, 2014), acellular cystic cavity formation (Kamada
et al., 2011), excessive and persistent neuroinflammation (Zhu et al.,
2015), expression of various axon-growth inhibitory molecules (Beller
and Snow, 2014), absence of trophic support (Robinson and Lu, 2017),
and the inadequate spatiotemporal production of axon guidance mole
cules to appropriately sculpt newly formed circuits (Sperry, 1963). In
addition to environmental factors, axon growth in the injured adult CNS
is limited by a number of important neuronal-intrinsic mechanisms such
as the PTEN-mTOR signaling axis (Park et al., 2010).
The extracellular matrix (ECM) plays essential roles in a variety of
biological processes within both the intact and diseased nervous system
such as cell migration, proliferation and differentiation. The ECM is also
is a major source of axon growth inhibitors (Barros et al., 2011; Franco
and Muller, 2011). In the CNS, the ECM is comprised of a number of
different molecules, including chondroitin sulfate proteoglycans
(CSPGs), non-collagenous glycoproteins, fibrillar collagens and hyalur
onan (Benarroch, 2015; Fawcett, 2015). CSPGs are normally expressed
in the intact spinal cord where they contribute to fundamental cellular
processes. CSPGs can be significantly upregulated after CNS injury,
resulting in growth inhibition of both damaged and spared axon pop
ulations (Lang et al., 2015; Tran et al., 2018). Following insults to the
CNS, increased CSPG secretion occurs in a number of cell types such as
astrocytes, fibroblasts, pericytes and inflammatory cells, in particular
within reactive scar tissue (Sharma et al., 2012). This upregulated CSPG
expression mediates axon growth inhibition by signaling through re
ceptors located on the membrane of axons, thereby limiting CNS plas
ticity and repair (Bartus et al., 2012; Kwok et al., 2011; Xu et al., 2015).
CSPGs can also induce caspase 3-mediated cell death in mature oligo
dendrocytes and in populations of neural precursors such as oligoden
drocyte progenitor cells (Dyck et al., 2019). By selectively cleaving the
glycosaminoglycan (GAG) side chains of CSPGs (which are responsible
for mediating a major portion of the axonal effects of CSPGs) via
introduction of the bacterial enzyme chondroitinase ABC (ChABC),
pioneering work has demonstrated that modulating the axon growth
inhibitory impact of CSPGs after SCI can promote growth of injured and
spared axons and some degree of functional recovery (Alilain et al.,
2011; Bradbury et al., 2002; Garcia-Alias et al., 2009; James et al., 2015;
Ramer et al., 2014). CSPGs may therefore be an important therapeutic
target for promoting repair following SCI.
Structurally, proteoglycans contain a protein core and GAG side
chains (chondroitin sulfate in the case of CSPGs). While it was initially
believed that CSPGs mediated their axon growth inhibitory effects by
2
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2. Results

et al., 2020). C2 hemisection axotomizes descending bulbospinal path
ways originating in the rVRG of the medulla, thereby interrupting their
connections to the PhMNs located at cervical levels C3-C5. Thus, a
hemiparalysis of the diaphragm occurs ipsilateral to the injury, while the
rVRG-PhMN-diaphragm circuit remains intact on the contralateral side.
The hemisected animal is able to maintain ventilation due to preserva
tion of both contralateral hemidiaphragm function and other non-

2.1. C2 hemisection SCI model and experimental design
Hemisection of the cervical level 2 (C2) spinal cord from the midline
to lateral edge has been used extensively to study respiratory plasticity
following SCI (Bezdudnaya et al., 2017; Mantilla et al., 2017; Streeter

Fig. 1. LAR peptide promoted recovery of diaphragm function after C2 hemisection SCI. (A) Timeline of experimental design. At 8 weeks post injury, EMG recordings
were assessed at 3 sub-regions of both the ipsilateral and contralateral hemidiaphragm (dorsal, medial and ventral sub-regions) from C2 hemisection rats receiving
either DMSO-only (B) or LAR peptide (C). (B, C) Representative EMG recordings from ipsilateral hemidiaphragm. Top: raw EMG traces; bottom: integrated signals.
Quantification of integrated EMG amplitude 8 weeks after C2 hemisection at ventral (D) medial (E) and dorsal (F) sub-regions. n = 8–10 animals per group. Data
represent mean ± SEM, *P < 0.05 vs the respective control.
3
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diaphragm respiratory muscle pathways. C2 hemisection SCI is a
powerful experimental model to mechanistically study plasticity of
respiratory neural circuitry using neuroanatomical labeling of various
components of this critically important circuit. In addition, various in
vivo assays can be employed to assess recovery of diaphragm function in
response to experimental manipulations, including therapeutic
strategies.
As shown in the experimental timeline (Fig. 1A), a biocompatible
gelfoam was soaked with either DMSO vehicle- only control or LAR
peptide and was placed directly over the SCI site immediately after C2
hemisection. The gelfoam was then replaced with fresh peptide (or
DMSO only) at 1 week post-injury. Two weeks post-SCI, we performed
stereotaxic intra-medullary injection of an AAV2-mCherry vector to
transduce either: (1) ipsilateral rVRG neurons or (2) contralateral rVRG
neurons. At 7 weeks post- injury, we performed in vivo compound
muscle action potential (CMAP) recording separately on each hemi
diaphragm to evaluate functional innervation of the diaphragm by
PhMNs. At 4 days after CMAP recording, we intrapleurally injected
Cholera Toxin B Subunit to selectively label PhMN cell bodies within the
cervical spinal cord. At 8 weeks post-injury, we performed in vivo
electromyography (EMG) recordings during normal eupnic breathing to
assess hemidiaphragm function, and animals were then euthanized for
tissue collection.

peptide treated groups. Quantification of contralateral hemidiaphragm
EMG amplitudes from each subregion was the following (in μV.s):
ventral, 8.0 ± 0.4 for DMSO versus 8.8 ± 0.4 for LAR peptide (Fig. 1D);
medial, 8.3 ± 0.4 for DMSO versus 8.7 ± 0.4 for LAR (Fig. 1E); dorsal,
9.4 ± 0.3 for DMSO versus 8.2 ± 0.4 for LAR (Fig. 1F), P > 0.05 for all
contralateral three subregions, one-way ANOVA, n = 8–10 rats per
group for each subregion. These data from the contralateral hemi
diaphragm show both that contralateral hemidiaphragm function was
not altered by LAR peptide and that we do not encounter significant
animal-to-animal variability in measuring diaphragm EMG amplitude.
Overall, EMG data demonstrate that treatment with LAR peptide
promotes ipsilateral hemidiaphragm functional improvement in vivo
compared to DMSO-only control. We next sought to mechanistically
explore how LAR inhibition is mediating this recovery.
2.3. LAR peptide did not affect functional innervation of the diaphragm
by PhMNs
Diaphragm functional deficits after C2 hemisection (as well as LAR
peptide experimentally-induced recovery) as reflected by EMG ampli
tude could be caused by dysfunction at a number of points along the
rVRG-PhMN-diaphragm pathway: central drive from rVRG neurons to
PhMNs, PhMN drive to diaphragm, or diaphragm muscle fiber activa
tion. We first tested whether hemisection-alone or LAR peptide treat
ment altered functional innervation of the diaphragm by PhMNs. To do
so, we performed in vivo quantitative recordings of CMAP amplitude
from the ipsilateral or contralateral hemidiaphragm in response to
supramaximal stimulation of the ipsilateral or contralateral phrenic
nerve, respectively. Using this approach, we activate all phrenic motor
axons and can then measure the post-synaptic depolarization response
across all muscle fibers in the hemidiaphragm muscle. Representative
traces of ipsilateral or contralateral hemidiaphragm CMAP responses are
shown in Fig. 2 (A, B for DMSO-only control group; C, D for LAR peptide
group). Quantitative analysis showed no differences in peak CMAP
amplitude (Fig. 2E), duration (data not shown) or latency (i.e. time from
stimulus to the initial CMAP deflection from baseline; data not shown)
between DMSO-only control and LAR peptide groups, including in both
the ipsilateral and contralateral diaphragm. The average peak CMAP
amplitude ipsilateral to the injury site was 7.2 ± 0.5 mV for DMSO-only
and 7.2 ± 0.7 mV for LAR peptide (n = 4 per group, P = 0.87, one-way
ANOVA), while average peak CMAP amplitude contralateral to the
hemisection was 6.7 ± 0.6 mV for DMSO and 6.6 ± 0.2 mV for LAR
peptide (n = 4 per group, P = 0.88, one-way ANOVA). These data
demonstrate that C2 hemisection did not alter functional innervation of
the diaphragm by PhMNs compared to the intact side and that in hem
isection animals LAR peptide treatment also did not affect functional
diaphragm innervation.

2.2. LAR peptide promoted recovery of diaphragm function after C2
hemisection SCI
Deficits in inspiratory diaphragm function can result from disruption
at a number of possible locations along the rVRG-PhMN-diaphragm
neural circuit, including rVRG axon status, rVRG axon-PhMN synaptic
connectivity, PhMN health, phrenic axon-diaphragm synaptic connec
tivity, and diaphragm muscle. In this study, we aimed to determine
whether peptide-based LAR inhibition can restore diaphragm function
after SCI and, importantly, by which mechanism of circuit plasticity this
recovery occurs using a comprehensive set of neuroanatomical and in
vivo functional assays.
We first examined diaphragm function by quantitively measuring
inspiratory bursting during normal eupnic breathing using in vivo EMG
recordings of the hemidiaphragm ipsilateral to the SCI. As rVRG-PhMN
disconnection after C2 hemisection results in nearly-complete EMG
silencing of the ipsilateral hemidiaphragm, recovery of EMG amplitudes
could be driven by LAR peptide-induced rVRG axon regeneration and
synaptic reconnection with PhMNs. The diaphragm is a dome-shaped
muscle at the base of the lungs, and under intact conditions, it con
tracts and moves downward allowing the lungs to expand during
inspiration; the diaphragm muscle relaxes during expiration. Ventral,
medial and dorsal subregions of each hemidiaphragm correspond to
innervation from PhMN cell bodies located at C3, C4 or C5 spinal cord,
respectively (Laskowski and Sanes, 1987); therefore, conducting EMG
recordings separately at each of these diaphragm subregions potentially
allows for correlating functional EMG effects with neuroanatomical
plasticity at these different spinal cord regions of the PhMN pool.
In the DMSO-only control group, we observed almost-silenced EMG
signals at all three subregions of hemi- diaphragm ipsilateral to the
hemisection (Fig. 1B), confirming that C2 hemisection disrupts rVRGPhMN-diaphragm signaling. On the contrary, we observed a signifi
cant recovery of diaphragm EMG amplitudes at both ventral and medial
sub-regions of ipsilateral hemidiaphragm after treatment with LAR
peptide (Fig. 1C). Quantification of ipsilateral hemidiaphragm EMG
amplitudes from each subregion was the following (in μV.s): ventral, 0.7
± 0.1 for DMSO versus 2.7 ± 0.4 for LAR peptide, P < 0.001 (Fig. 1D);
medial, 0.6 ± 0.1 for DMSO versus 1.4 ± 0.3 for LAR, P = 0.03, (Fig. 1E);
dorsal, 0.6 ± 0.1 for DMSO versus 1.0 ± 0.1 for LAR, P = 0.4 (Fig. 1F), n
= 8–10 rats per group for each subregion. We also compared EMG
amplitude at all three subregions of hemidiaphragm contralateral to the
hemisection and found no differences between DMSO-only and LAR

2.4. LAR peptide did not affect morphological innervation of the
diaphragm by PhMNs
Previous work from our lab and others demonstrated that cervical
contusion-type SCI models that produce damage to PhMN cell bodies
within the C3-5 spinal cord result in significant morphological dener
vation at the diaphragm neuromuscular junction (NMJ) (Nicaise et al.,
2013; Nicaise et al., 2012a; Nicaise et al., 2012b), the critical synapse
between phrenic motor axons and diaphragm muscle fibers. At eight
weeks after injury, we morphologically determined whether NMJ
innervation was compromised after C2 hemisection SCI and whether
LAR peptide treatment affected this important synapse. Specifically,
using whole-mount immunohistochemistry of the muscle, we labeled
post-synaptic nicotinic acetylcholine receptors with fluorescentlyconjugated alpha-bungarotoxin (red), and we labeled pre-synaptic
phrenic motor axons all the way to their terminals with an antibody
against neurofilament (SMI-312, green) and a second antibody against
synaptic vesicle protein 2 (SV2, also green). As shown in representative
4
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Fig. 2. LAR peptide did not affect functional innervation of the diaphragm by PhMNs. Representative CMAP recordings obtained from the ipsilateral and contra
lateral hemidiaphragm of DMSO-only (A-B) and LAR peptide (C-D) groups. (E) Quantification of CMAP amplitudes showed no differences between the DMSO-only
and LAR peptide groups or between ipsilateral and contralateral hemidiaphragm. n = 4 animals per group, P > 0.05.

19 ± 2 rVRG neurons per section; LAR: 24 ± 5, P = 0.32, t-test, n = 4 rats
per group, Fig. 4C-E).
To histologically verify lesion completeness before performing rVRG
axon regeneration analysis, we performed both GFAP immunostaining
(Fig. 4F-H) and and cresyl violet staining (data not shown) on cervical
spinal cord sections from DMSO-only and LAR peptide rats. We found
that the C2 hemisection was anatomically complete in every rat. In a
separate cohort of rats receiving C2 hemisection-only (but no LAR
peptide or DMSO-only treatment), we observed silencing of ipsilateral
hemidiaphragm EMG activity at two weeks post-injury (i.e. a time point
before the small amount of spontaneous ipsilateral EMG recovery occurs
in the C2 hemisection model) in all tested animals (n = 5 rats; data not
shown), further supporting the completeness of our lesion. While these
EMG recordings at 2 weeks post-injury were not conducted in the
injured rats receiving LAR peptide or DMSO-only, these data neverthe
less support the consistent completeness of our C2 hemisection surgical
procedure.
In addition, we quantified lesion size to determine whether LAR
peptide treatment impacted the histological extent of spinal cord dam
age compared to the DMSO-only control group, which could contribute
to LAR peptide-induced functional recovery. To measure lesion size, we
performed GFAP immunohistochemistry on sagittal spinal cord sections
to identify the border between intact tissue and lesion. We quantified
rostral-caudal distance from the rostral to caudal borders of the lesion
and found no difference between the experimental groups (Fig. 4F-H):
393.8 ± 59.6 μm in DMSO-only group; 362.8 ± 36.6 μm in LAR peptide
group, P = 0.67, t-test, n = 4 rats per group. These data suggest that a
neuroprotective effect of LAR peptide was not involved in the observed
functional diaphragm recovery.
Transduction of the rVRG neuronal cell bodies resulted in antero
grade labeling of rVRG axons within the cervical spinal cord. Sagittal
spinal cord sections from animals with ipsilateral rVRG labeling were
triple immunostained with DsRed (to enhance mCherry signal), vesic
ular glutamate transporter 2 (VGLUT2) to label excitatory presynaptic
terminals (as rVRG neurons are glutamatergic) and CTB (to selectively
label PhMN cell bodies). CTB-labeled PhMNs were continuously
distributed in a column within the ventral grey matter extending along
levels C3 to C5 (Fig. 5A). rVRG axon regeneration was quantified as the
number of mCherry tracer-labeled rVRG axons at different distances
rostral to the lesion site, within the lesion, and in the caudal intact spinal
cord (Fig. 5A).
Both DMSO-only and LAR peptide treated animals showed rVRG
axons rostral to the lesion (Fig. 5B,E). However, in the DMSO-only
group, no rVRG axons were observed regrowing into or through the
lesion (Fig. 5C) or into the caudal spinal cord (Fig. 5D), consistent with
the results of our previous studies with untreated C2 hemisection-only
conditions (Charsar et al., 2019; Urban et al., 2019a). In the LAR

confocal z-stacks, nearly all NMJs in the ipsilateral hemidiaphragm were
intact in C2 hemisection animals receiving either DMSO-only (Fig. 3A-F)
or LAR peptide (Fig. 3G-L). Intact NMJs are characterized by complete
apposition of the pre- and post-synaptic labeling. To quantitatively
assess this innervation, we identified three primary NMJ morphologies:
intact innervation (99.2 ± 0.4% of all NMJs in DMSO-only, n = 3 versus
99.5 ± 0.3%, n = 4 in LAR peptide; P > 0.05 by ANOVA); partial
denervation (0.25 ± 0.25% in DMSO, n = 3; 0.20 ± 0.20% in LAR
peptide, n = 4; P > 0.05 by ANOVA), in which there is only partial
overlap of the motor axon with the post-synaptic receptors; complete
denervation (0.0 ± 0.0% in DMSO, n = 3 versus 0.0 ± 0.0% in LAR
peptide, n = 4; P > 0.05 by ANOVA). There were no differences in the
percentages of intact, partially-denervated or completely-denervated
NMJs between rats treated with DMSO-only and LAR peptide
(Fig. 3M). In addition, LAR peptide had no effect on the portion of NMJs
innervated by multiple phrenic motor axons (0.67 ± 0.34% in DMSO, n
= 3; 0.25 ± 0.25% in LAR peptide, n = 4; P > 0.05 by ANOVA) or the
percentage of NMJs with thin preterminal axons, a phenotype indicative
of denervation and subsequent reinnervation (0.0 ± 0.0% in DMSO, n =
3; 0.0 ± 0.0% in LAR peptide, n = 4; P > 0.05 by ANOVA) (Fig. 3M).
These NMJ and CMAP results (i.e. absence of both functional and
morphological denervation of the diaphragm by PhMNs on the side of
hemisection SCI) were not unexpected given that the SCI was conducted
at C2, which is just rostral to the rostral-most-part of the phrenic nu
cleus. Combined with the CMAP findings, these NMJ data also demon
strate that LAR peptide delivery did not promote functional recovery by
affecting PhMN innervation of the diaphragm.
2.5. LAR peptide promoted rVRG axon regeneration through the lesion
and into the intact caudal spinal cord
After CNS injury, damaged axons are unable to regenerate in mam
mals without therapeutic intervention, including rVRG axons (Charsar
et al., 2019; Urban et al., 2019a; Urban et al., 2019b). Even with
experimental manipulation of axon growth inhibitory mechanisms
(especially using non-genetic approaches), it is extremely challenging to
achieve long-distance axon regeneration, in particular through the
lesion site and back into the distal intact spinal cord where regenerating
axons could connect with post-synaptic neuronal targets. To determine
whether LAR peptide treatment promoted rVRG axon regeneration, we
selectively labeled only rVRG axons by transducing rVRG neurons
within the medulla ipsilateral to the hemisection with AAV2-mCherry
(Fig. 4A). To determine whether our AAV2-mCherry labeling strategy
was consistent across animals both within and across groups, we
quantified the number of transduced rVRG cell bodies in the medulla.
There was no difference in the number of AAV2-mCherry transduced
rVRG neuron cell bodies between the two experimental groups (DMSO:
5
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Fig. 3. LAR peptide did not affect morphological innervation of the diaphragm by PhMNs. Whole-mount immunohistochemistry of diaphragm was used to label postsynaptic nicotinic acetylcholine receptors with AlexaFluor- conjugated alpha-bungarotoxin (red) and pre-synaptic phrenic motor axons all the way to their terminals
with an antibody against neurofilament (SMI-312, green) and a second antibody against synaptic vesicle protein 2 (SV2, also green). As shown in representative
confocal z-stacks, nearly all NMJs in ipsilateral hemidiaphragm were intact in C2 hemisection animals receiving either DMSO-only (A-F) or LAR peptide (G-L). As
shown in the higher magnification images, intact NMJs were characterized by complete apposition of the pre- and post-synaptic labeling. There were no differences
in the percentages of intact, completely-denervated (Denv) or partially-denervated (P.Denv) NMJs, the portion of NMJs innervated by multiply phrenic motor axons
(M.A.) or the percentage of NMJs with thin preterminal axons (T.S.) between rats treated with DMSO-only and LAR peptide (M). n = 3 for DMSO-only, n = 4 for LAR
peptide. P > 0.05 vs the respective control. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

peptide group, we observed significant growth of rVRG axons across the
rostral intact-lesion interface, across the lesion site and across the caudal
lesion-intact interface (Fig. 5F), and finally for several segments along
the intact caudal spinal cord (Fig. 5G). Quantification of mCherry+ axon
regrowth profiles at different rostral-caudal distances (Fig. 5H) shows
that LAR peptide was effective at stimulating rVRG axon regeneration
across an anatomically-complete SCI lesion, with these axons even
reaching the C3 (corresponding to 1500 μm bar in Fig. 5H), C4 (corre
sponding to 3000 μm bar in Fig. 5H) and C5 (corresponding to 4500 μm
bar in Fig. 5H) spinal cord segments (asterisk indicates P < 0.05,
ANOVA, n = 4 per group). Furthermore, to explore the relationship
between rVRG axon regeneration and functional EMG improvement
induced by LAR peptide, we examined the correlation between the de
gree of rVRG axon regeneration at the C3 level and EMG amplitude in
the corresponding ventral diaphragm subregion (Fig. 5I). There was a
correlation between these two outcomes in the LAR peptide group
(correlation coefficient for linear fit, R2 = 0.98, P = 0.01); data from
DMSO-only control were not included in this analysis as absolutely no
rVRG axon regeneration was observed in this group. These findings
suggest that regeneration of rVRG axons across the lesion and into the
intact caudal spinal cord (i.e. the location of the PhMN pool) was at least
in part responsible for the recovery of diaphragm function induced by
LAR peptide.

significant, the trend toward an increase suggests that LAR peptide may
also enhance excitatory synaptic input to PhMNs from other neuronal
populations in addition to rVRG axons (e.g. possibly from excitatory
interneurons, sensory afferents, and various projection neuron pop
ulations originating in supraspinal locations other than rVRG).
2.7. LAR peptide promoted sprouting of rVRG axons within the PhMN
pool
Axon sprouting, defined as fine nerve processes or “sprouts” that
grow out from injured or spared axons, has long been considered an
important form of plasticity that can drive recovery of function both
spontaneously and in response to therapeutic intervention following
CNS damage (Meves and Zheng, 2014). We examined whether sprouting
of spared rVRG axons originating in the contralateral medulla was
induced by LAR peptide by injecting the AAV2-mCherry anterograde
tracer into the contralateral rVRG and then quantifying sprouting of
these axons within the PhMN pool on the side of the hemisection (i.e.
contralateral to the location of their cell bodies) (Fig. 4B). Sagittal spinal
cord sections were double-immunolabeled with DsRed and CTB. We
then counted numbers of mCherry+ fibers within the phrenic nucleus (i.
e. the location of CTB+ PhMNs) at distances of 1.5 mm, 3.0 mm and 4.5
mm caudal to the lesion that correspond to C3, C4 and C5 levels,
respectively (Fig. 7A). Representative confocal images show PhMNs
labeled with CTB that were surrounded by contralateral-originating
mCherry+ rVRG axons (Fig. 7B-G). We observed that these
contralateral-originating rVRG axons are present within the PhMN pool
on the side of hemisection even in the DMSO-only condition (Fig. 7D, H).
The average number of these mCherry+ fibers in the LAR peptide group
(11.8 ± 0.6, n = 5) increased significantly (P < 0.001, one-way ANOVA
analysis, Fig. 7E-G, 7I, 7K) compared to DMSO-only control (3.4 ± 0.8, n
= 5) at C3 (Fig. 7B-D, 7H, 7K) and C4 (2.7 ± 0.3 in DMSO, n = 5; 8.7 ±
1.3 in LAR peptide, n = 5; P = 0.002, one-way ANOVA, Fig. 7L), but
there was no statistical significance in the difference at C5 (3.2 ± 0.8 in
DMSO, n = 5 versus 7.1 ± 1.5 in LAR peptide, n = 5; P = 0.052, one-way
ANOVA, Fig. 7M). We next examined whether there was a relationship
between this sprouting and diaphragm functional recovery by assessing
the correlation between the degree of rVRG axon sprouting at the C3
level and EMG amplitude in the corresponding ventral diaphragm sub
region (Fig. 7J). Unlike with the correlation between rVRG axon
regeneration and EMG amplitude (Fig. 6I), we found no correlation
between rVRG axon sprouting and diaphragm recovery (R2 = 0.75; P =
0.14).

2.6. LAR peptide promoted putative monosynaptic connection between
regenerating rVRG axon and PhMNs
Achieving long-distance axon regeneration following SCI is a major
challenge. In addition to this axonal regrowth, it is also critical for these
axons to synaptically connect with appropriate neuronal targets to
promote recovery of function. This synaptic integration can include
connectivity with the original post-synaptic targets of the axotomized
neurons and/or generation of circuitry via novel connections. To
investigate whether regenerating ipsilateral-originating rVRG axons
formed synaptic connections with PhMNs on the side of hemisection SCI,
we assessed the number of putative synaptic connections specifically
between mCherry/DsRed-positive rVRG fibers and CTB-labeled PhMN
cell bodies at level C3 using confocal acquisition of z-stacks and quan
tification of rVRG axon-PhMN contacts using single-Z section analysis to
establish direct apposition of pre-synaptic VGLUT2+/mCherry+ axon
terminals and post-synaptic CTB+ PhMNs. We observed no putative
rVRG-PhMN synapses in the DMSO-only control (Fig. 6A-D), as expected
since no rVRG axon regeneration was achieved in this group. On the
contrary, we observed large numbers of putative rVRG-PhMN synapses
in the LAR peptide group (Fig. 6E-H). We quantified the number of these
synaptic connections per individual PhMN at C3 and then plotted these
data against the EMG amplitude results from the corresponding ventral
subregion (Fig. 6I); there was strong correlation between these datasets
(R2 = 0.99; P < 0.0001), further supporting the notion that rVRG axon
regeneration and rVRG-PhMN circuit reconnectivity at least in part was
responsible for LAR peptide-induced functional recovery. In addition to
putative excitatory synapses between mCherry+ rVRG axons and
PhMNs, we also quantified the effects of LAR peptide on excitatory
synapses from mCherry− /VGLUT2+ non-rVRG inputs on ipsilateral
CTB+ PhMNs at C3: 11.8 ± 0.9 putative mCherry− /VGLUT2+ excitatory
synapses per CTB+ PhMN in DMSO-only group; 16.4 ± 1.9 in LAR
treated group, P = 0.07, t-test, n = 4 rats per group, Fig. 6J. While not

2.8. LAR peptide promoted sprouting of modulatory serotonergic axons
within the PhMN pool
Modulatory serotonergic axons whose cell bodies reside in one of
several raphe nuclei of the brain play an important role in regulating the
excitability of neuron populations across the CNS, in particular spinal
cord lower motor neurons such as PhMNs (Fisher et al., 2011).
Furthermore, plasticity of this serotonergic input has been shown to be
involved in recovery of diaphragm function after cervical SCI, including
both in the absence and presence of therapeutic intervention (Gosh
garian, 2003; Perrin and Noristani, 2019). At 8 weeks post-injury, we
assessed the density of serotonergic axon innervation within the PhMN
pool by performing immunohistochemistry for serotonin (5-HT) and
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Fig. 4. Labeling of rVRG-PhMN circuitry. (A) To determine whether LAR peptide treatment promoted rVRG axon regeneration, we selectively transduced rVRG
neurons within the medulla ipsilateral to the hemisection with AAV2- mCherry. (B) In a separate cohort of rats, we examined whether sprouting of spared rVRG axons
originating in the contralateral medulla was induced by LAR peptide by injecting the AAV2-mCherry anterograde tracer into the contralateral rVRG and then
quantifying sprouting of these axons within the PhMN pool on the side of the hemisection (i.e. contralateral to the location of their cell bodies). In both cohorts, we
intrapleurally injected Cholera Toxin B Subunit (CTB) to selectively label PhMN cell bodies within the cervical spinal cord. There was no difference in the number of
AAV2-mCherry transduced rVRG neuron cell bodies in the medulla between the DMSO-only (C) and LAR peptide (D) groups (P = 0.32, n = 4 per group); quan
tification in (E). Sagittal spinal cord sections immunolabeled for GFAP from DMSO-only control (F) and LAR peptide (G) show that LAR peptide did not alter lesion
size after C2 hemisection. (H) Quantification of GFAP-labeled sections shows no difference in lesion size as measured by the rostral-caudal distance from the rostral to
caudal borders of the lesion (P = 0.67, n = 4 rats per group).

quantifying the total length of 5-HT+ axons. Compared to DMSO-only
control (Fig. 8A-B), LAR peptide significantly increased the total 5-HT
axon length within the phrenic nucleus at C3 (Fig. 8B-C) (3376 ± 779
μm in DMSO versus 8473 ± 1562 μm in LAR peptide, n = 6 per group
animals, P = 0.02, one-way ANOVA). However, LAR peptide did not
affect the density of 5-HT axon innervation of the PhMN pool at C4
(5135 ± 1861 in DMSO; 6952 ± 1501 in LAR peptide, n = 6 per group

animals, P = 0.42, one-way ANOVA; Fig. 8D) or C5 (4973 ± 2109 in
DMSO; 6657 ± 1461 in LAR peptide, n = 6 per group animals, P = 0.44,
one-way ANOVA; Fig. 8E).
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Fig. 5. LAR peptide promoted rVRG axon regeneration through the lesion and into the intact caudal spinal cord. (A) Sagittal section of cervical spinal cord showing
the columnar organization of CTB-labeled PhMNs extending from C3 to C5, the locations (i.e. rostral-caudal distances relative to the hemisection site) of rVRG axon
growth analysis, and the location of the representative images in panels B-G; scale bar in (A): 250 μm. Representative images of sagittal sections from DMSO-only or
LAR peptide treated rats injected with AAV2-mCherry into the ipsilateral rVRG: (B,E) rostral to lesion site, (C,F) lesion site, (D,G) caudal to lesion site. These images
from the two groups were always taken from the same rostral-caudal position/distance relative to the lesion epicenter. Yellow arrows in panels B-G denote mCherrylabeled rVRG axons. Dotted yellow lines in panels C and F denote the rostral and caudal lesion-intact borders. Scale bar: 100 μm. (H) Quantification shows the
numbers of ipsilateral-originating mCherry-labeled rVRG axons at different locations in DMSO-only and LAR peptide group using the rostral end of the lesion as the
rostral-caudal starting point. The indicated differences were compared between DMSO-only and LAR peptide groups at each distance (n = 4 animals per group, *P <
0.05). (I) Pearson Correlation was used to examine the correlation between the degree of rVRG axon regeneration at the C3 level and EMG amplitude in the cor
responding ventral diaphragm subregion (correlation coefficient for linear fit, R2 = 0.98, P = 0.01, n = 4 animals per group). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)

3. Discussion

lesion, across the lesion, and back out of the lesion into the distal/caudal
spinal cord (even if we have not tracked single axons along this entire
journey). Alternative explanations are possible, including that some of
these ipsilateral-originating rVRG axons (that we observe in the ispi
lateral PhMN pool in response to LAR peptide) are normally located in
the contralateral cervical spinal cord and that LAR inhibition caused
them to sprout across the spinal cord to reach the ipsilateral PhMN pool.
This would not explain the lack of these ipsilateral-originating rVRG
axons in the ipsilateral PhMN pool in the DMSO-only condition in the
context of “double-crossing”, as we would expect to see them there even
in the absence of therapeutic manipulation. It is possible that multiple
plasticity mechanisms are occurring; nevertheless, our data strongly
suggest that regeneration of injured ipsilateral-originating rVRG axons
was significantly involved in the observation of these axons in the
ipsilateral PhMN pool caudal to the hemisection.

3.1. Long-distance regeneration versus sprouting
We find that LAR peptide administration resulted in both regenera
tion of injured rVRG axons and sprouting of spared rVRG and seroto
nergic axons. Our results are not in line with the body of work suggesting
that modulating CSPG-mediated axon growth inhibition stimulates local
sprouting and synaptic rearrangement but not long-distance regenera
tion (reviewed in (Sofroniew, 2018)), though other studies have shown
the axon regeneration promoting effects of targeting CSPGs after CNS
injury (Bradbury et al., 2002). The current work and our previous
studies (Urban et al., 2019b) demonstrate that rVRG axons are robust
regenerators in response to targeting of growth inhibitory mechanisms;
therefore, one possible explanation may be that the axon growth
phenotype (i.e. regeneration versus sprouting) may differ with the spe
cific axon population being examined. Interestingly, our previous work
with a PTPσ inhibitory peptide showed functional diaphragm recovery
in the C2 hemisection model (employing the same peptide delivery
approach as we used for LAR peptide), but no regeneration of rVRG
axons; instead, we found only sprouting of spared rVRG axons within the
ipsilateral PhMN pool in response to PTPσ peptide (Urban et al., 2019a).
These differences in the plasticity of rVRG-PhMN circuitry between LAR
and PTPσ peptides may be explained by the findings that PTPσ and LAR
can signal in part through non-overlapping intracellular transduction
pathways that may be regulating different axon growth responses
(Ohtake et al., 2016). Furthermore, our current and previous data
collectively provide rationale for the combination of both PTPσ and LAR
inhibition to maximize recovery via the simultaneous modulation of
multiple signaling pathways and consequently multiple forms of axon
growth (Ohtake et al., 2016).
Using our analysis of only 40 μm thick spinal cord sections, we are
not tracking regeneration of individual rVRG axons over long distances;
therefore, caution is needed in making the conclusion that LAR peptide
promoted regeneration of injured rVRG axons across the lesion site and
back into the caudal intact C3-C5 spinal cord. However, we do clearly
observe in every LAR-treated animal individual rVRG axons growing
across the rostral intact-lesion interface into the lesion site, and we
similarly observe in every LAR-treated animal individual rVRG axons
growing across the caudal lesion-intact interface back into the caudal
intact spinal cord. Furthermore, we never observe this in any animal in
the DMSO-only control group. Therefore, while we have not followed
individual axons along this entire journey, the data strongly suggest that
they regenerated through the lesion.
Findings in the field suggest that there is some double-crossed rVRG
input to the PhMN pool originating in the ipsilateral rVRG (i.e. rVRG
axons cross and then re-cross back as they descend from the medulla to
the phrenic nucleus) (Boulenguez et al., 2007). Interestingly, we
observed absolutely no ipsilateral-originating rVRG axon labeling
within the PhMN pool ipsilateral to the hemisection in the DMSO-only
control group, suggesting that the ipsilateral-originating rVRG axons
that we observe at this location in the LAR peptide group made it there
by growing through (and/or around) the lesion. This is supported by our
observations of ipsilateral-originating rVRG axons growing into the

3.2. Mechanism of axon growth driving functional recovery
In this study, we sought to determine which axon growth mechanism
(s) stimulated functional diaphragm recovery in response to LAR pep
tide. It is particularly challenging to determine the mode(s) of circuit
plasticity causally responsible for recovery of function in an in vivo
model of SCI. Along these lines, we have not definitively determined
whether regeneration, sprouting or a combination of both drove dia
phragm recovery, though we do provide a large amount of functional
and neuroanatomical data that shed significant light on this important
question.
We observe significant regeneration of injured rVRG axons into and
through the lesion site and, importantly, back into the distal intact spinal
cord where they reach the cell bodies of the PhMNs ipsilateral to the
hemisection. Interestingly, we find that this rVRG axon regeneration was
the most robust at the C3 and C4 levels, with significantly less regen
eration at the more caudal C5 segment (Fig. 5H). Correspondingly, we
find diaphragm recovery with our EMG recordings only at the ventral
and medial subregions of the muscle that are innervated by PhMNs
primarily located at C3 and C4, respectively, but not at the dorsal sub
region that is controlled by C5 PhMNs (Fig. 1 D-F). In addition, we find
that there is some degree of animal-to-animal variability in both EMG
recovery and rVRG axon regeneration in response to LAR peptide and
that this recovery is strongly correlated with the amount of rVRG axon
regeneration (Fig. 5I). Similarly, EMG recovery correlated with the de
gree of rVRG-PhMN monosynaptic connections within the ipsilateral
spinal cord (Fig. 6I). Collectively, these data suggest that rVRG axon
regeneration was possibly responsible - at least in part - for driving
functional diaphragm recovery.
In our published work with a PTEN antagonist peptide, we also found
robust rVRG axon regeneration and diaphragm recovery in the C2
hemisection model (Urban et al., 2019b). In this previous study, we
found that re-lesion through the hemisection site completely ablated
recovery, demonstrating that regeneration through the injury site was
causally responsible specifically for PTEN inhibition-induced improve
ment and more generally that long-distance axon regeneration is a
growth mechanism that can lead to diaphragmatic recovery after SCI
(which has also been shown by Alilain and colleagues (Alilain et al.,
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Fig. 6. LAR peptide promoted putative monosynaptic connection between regenerating rVRG axon and PhMNs. We assessed the number of putative synaptic
connections specifically between mCherry/DsRed-positive rVRG axons and CTB-labeled PhMN cell bodies at level C3 with confocal acquisition of z-stacks and
quantification of rVRG axon-PhMN contacts using single-Z section analysis to establish direct apposition of pre-synaptic VGLUT2+/mCherry+ axon terminals and
post-synaptic CTB+ PhMNs. Representative images in panels A-H are compressed z-stacks. (A-D) We observed no putative rVRG-PhMN synapses in the DMSO-only
control. (E-H) On the contrary, we observed large numbers of putative rVRG-PhMN synapses in the LAR peptide group. (I) Orthogonal projection shows mCherry+/
VGLUT2+ excitatory rVRG axon terminals located directly presynaptic to the soma of a CTB+ PhMN (example putative connections denoted by arrowheads). Scale
bar: 100 μm. Quantification of the number of these synaptic connections per individual PhMN at C3 plotted against the EMG amplitude from the corresponding
ventral subregion in LAR peptide group (R2 = 0.99; P < 0.0001, n = 4). (J) Quantification of the effects of LAR peptide on putative excitatory synapses from
mCherry− /VGLUT2+ non-rVRG inputs per ipsilateral PhMN at C3 (P = 0.07, n = 4 rats per group).
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Fig. 7. LAR peptide promoted sprouting of rVRG axons within the PhMN pool. (A) Sagittal section of cervical spinal cord showing the columnar organization of CTBlabeled PhMNs extending from C3 to C5, the locations of rVRG axon growth analysis, and the location of the representative images in panels B-D as well as E-G.
Sagittal spinal cord sections were double-immunolabeled with DsRed (to enhance the mCherry signal) and CTB. We counted numbers of mCherry+ fibers within the
phrenic nucleus (i.e. the location of CTB+ PhMNs) at distances of 1.5 mm, 3.0 mm and 4.5 mm caudal to the lesion that correspond to C3, C4 and C5 levels,
respectively; scale bar in (A): 250 μm. Representative confocal images show PhMNs labeled with CTB that were surrounded by mCherry+ rVRG axons. Contralateraloriginating rVRG axons are present within the PhMN pool on the side of hemisection in both the DMSO-only (B-D) and LAR-peptide treated (E-G) conditions. (H, I)
Yellow arrows indicate mCherry-labeled rVRG axons only. Scale bars: 100 μm. (F) The number of these mCherry+ fibers in the LAR peptide group increased
significantly compared to DMSO-only control at C3 (E-I, K) and C4 (L), but there was no significant difference at C5 (M) (P < 0.05). (G) Pearson Correlation was used
to examine the correlation between the degree of rVRG axon sprouting at the C3 level and EMG amplitude in the corresponding ventral diaphragm subregion in the
LAR peptide group (correlation coefficient for linear fit, R2 = 0.75; P = 0.14, n = 5). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)

2011). We did not perform a similar re-lesion experiment in the current
study with LAR peptide, leaving the possibility open that input from the
spared contralateral spinal cord was the key mechanism (or that the
combination of input from both the ipsilateral and contralateral sides
together promoted functional improvement). To this point, we found
significant sprouting within the ipsilateral PhMN pool of spared rVRG
axons originating in the contralateral rVRG (Fig. 7). This finding is in
line with a number of studies that have shown that CSPG modulation in
the injured CNS promotes local sprouting (Sofroniew, 2018). Further
more, sprouting of spared circuitry is an important plasticity mechanism
that has been shown to promote functional recovery in SCI models both
spontaneously and in response to therapeutic interventions (Bareyre
et al., 2004). Importantly, achieving long-distance axon regeneration
and reconnection of original circuitry is not necessary for promoting
recovery after SCI. In the context of respiratory neural circuitry, spared
contralateral-originating rVRG input plays a central role in the small
amount of diaphragm recovery that occurs after C2 hemisection SCI,
both spontaneously and in response to various manipulations (Gosh
garian, 2003). Enhancing this spared input to the phrenic nucleus is a
potentially powerful approach for stimulating respiratory recovery postSCI. Interestingly, we observed rVRG axon sprouting at C3 and C4, but
not at C5, which corresponds to the pattern of EMG recovery at two of
the three diaphragm subregions. However, we did not find a correlation
between the degree of rVRG axon sprouting and EMG amplitude
(Fig. 7J), suggesting that this plasticity mechanism may not have played
a role in recovery (or played a lesser role than rVRG axon regeneration).
In another of our previous studies, we found in the C2 hemisection
model that PTPσ inhibitory peptide promoted recovery of diaphragm
function in the absence of any rVRG axon regeneration (Urban et al.,
2019a). Instead, PTPσ peptide stimulated robust sprouting of rVRG
axons within the ipsilateral phrenic nucleus, and we observed that relesion through the hemsiection site had no effect on diaphragm recov
ery, demonstrating that functional efficacy was based primarily on input
from the spared contralateral spinal cord after PTPσ inhibition.
Furthermore, we observed serotonergic axon sprouting within the
ipsilateral phrenic nucleus at C3, but not at C4 or C5. These data may
suggest that the combination of the highest level of rVRG axon regen
eration in the C3 spinal cord plus 5-HT axon sprouting at this same
location together produced the most significant EMG recovery in the
ventral diaphragm subregion, which is in line with the modulatory effect
of serotonergic input on glutamatergic neurotransmission in spinal
motor neurons (Dale-Nagle et al., 2010). Functional recovery was also
noted in the medial diaphragm; however, this recovery was not as robust
as in the ventral diaphragm, and it was accompanied by lesser rVRG
axon regeneration to the C4 spinal cord and an absence of 5-HT axon
sprouting within the C4 portion of the ipsilateral PhMN pool. It is sur
prising that we found increased density of 5-HT axons within the C3, but
not C4 or C5 PhMN pool, if this effect was due to a sprouting response.
Instead, we would expect to see equivalent 5-HT axon sprouting across
the phrenic nucleus. A possible explanation is that the greater density of
5-HT axons at C3 is due instead to regeneration of 5-HT axons across the
lesion site, with these axons first reaching C3 and then not extending
farther in the caudal direction. A number of studies have demonstrated
growth of serotonergic axons in response to manipulation of CSPG

signaling after SCI. For example, Lang and colleagues showed that de
livery of a PTPσ inhibitory peptide stimulates significant 5-HT axon
growth caudal to the thoracic SCI site, as well as recovery of bladder
function (Lang et al., 2015). In the context of damaged respiratory cir
cuitry, we have shown that PTEN antagonist peptide (Urban et al.,
2019b), PTPσ inhibitory peptide (Urban et al., 2019a), BDNF-releasing
hydrogel (Ghosh et al., 2018) and intraspinal injection of an AAV2BDNF vector (Charsar et al., 2019) each can promote 5-HT axon
sprouting within the PhMN pool in C2 hemisection and mid-cervical
contusion models of SCI. Warren and colleagues also showed that
Chondroitinase ABC delivery can promote significant serotonergic axon
growth and diaphragm recovery in the chronically injured cervical
spinal cord (Warren et al., 2018). Collectively, our studies and the work
of others in the field suggest that plasticity of serotonergic input to
PhMNs is an important mechanism for stimulating diaphragmatic re
covery after SCI and that targeting CSPG signaling via LAR and PTPσ
manipulation is a promising approach for achieving this goal.
An intriguing possibility is that different circuit plasticity mecha
nisms were responsible for driving recovery at different portions of the
PhMN pool in response to LAR inhibition. Going forward, it will be
important to utilize experimental approaches such as selective silencing
of specific neuronal populations using techniques like chemogenetics
(Roth, 2016) to explore this issue more comprehensively and with
greater experimental precision.
Another possible explanation for our observation of functional re
covery at the ventral and medial (but no dorsal) muscle subregions could
be due to a LAR peptide gradient, with the highest peptide levels closest
to the site of gelfoam delivery at C2 and progressively decreasing levels
at more caudal locations along the PhMN pool contributing (completely
or in part) to the differential functional effects observed across the three
muscle sub-regions. Moving forward, we could begin to explore this idea
by measuring peptide levels at different neuroanatomical locations.
3.3. Synaptic connections
The improvement of diaphragm function with LAR peptide could
have been due to direct effects on synaptic rearrangement instead of (or
in addition to) axon growth responses. Such synaptic effects could
modulate the input from spared and/or regenerating axon populations.
Previous work has shown that RPTPs such as LAR and PTPσ play an
important role in synaptic development, in particular of excitatory
synapses (Takahashi and Craig, 2013; Um and Ko, 2013). In this study,
we find significant numbers of putative monosynaptic connections be
tween regenerating rVRG axons and PhMN somata across the phrenic
nucleus. As we observe absolutely none of these putative synapses in the
DMSO-only control condition, the generation of these synapses may
have been due just to LAR peptide promoting rVRG axon regeneration,
with some of these regenerating axons making connections with PhMNs
because of proximity and not because LAR inhibition directly enhanced
synaptogenesis. We did not quantify monosynaptic connections between
contralateral-originating rVRG axons and PhMNs in our study; going
forward, this could be a useful approach to explore this question as we
could control for the density of rVRG axons surrounding the PhMN
somata and thereby assess LAR peptide’s effects specifically on levels of
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Fig. 8. LAR peptide promoted sprouting of modulatory serotonergic axons within the PhMN pool. At 8 weeks after hemisection SCI, we assessed the density of
serotonergic axon innervation of the PhMN pool on the side of injury by performing immunohistochemistry for serotonin (5-HT) and quantifying the total length of 5HT+ axons. Sagittal sections of the cervical spinal cord show that, compared to DMSO-only control (A), LAR peptide significantly increased 5-HT axon sprouting
within the ipsilateral phrenic nucleus at C3 (B–C) at 8 weeks post-injury (n = 6 animals per group, *P = 0.02). However, LAR peptide did not affect the density of 5HT axon innervation of the ipsilateral PhMN pool at C4 (D; P = 0.42) or C5 (E; P = 0.44). Scale bar: 100 μm. Arrowheads indicate 5-HT+ axons.
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synapse formation independent of sprouting.

methods such as systemic or intrathecal delivery (Urban et al.,
2019b). We have previously shown that systemic delivery of PTEN
antagonist peptide can promote diaphragm recovery in this same hem
isection model (Urban et al., 2019b), suggesting that a similar approach
with our LAR peptide may be feasible. In this study, we restricted our
approach to only a single peptide dosing and duration paradigm. It will
be interesting to determine whether we can enhance therapeutic effects
with a modified peptide delivery protocol. In addition to LAR peptide,
there exist a number of possible approaches to modulate CSPG signaling
such as enzymatic GAG side chain removal from CSPGs (Bradbury et al.,
2002), antibody-based (Wu et al., 2017) or small molecule (Keough
et al., 2016) targeting of LAR and PTPσ, and modulation of other RPTPs
besides LAR such as PTPσ (Urban et al., 2019a). It will be interesting
moving forward to compare the therapeutic efficacy, potential side ef
fects and various practical advantages and disadvantages of these
different approaches in cervical SCI models and specifically on respira
tory improvement. Finally, it is unlikely that LAR inhibition alone will
be sufficient for achieving maximal functional recovery. Our current
work demonstrates the therapeutic power of this novel LAR peptide
approach and also provides extensive data suggesting the plasticity
mechanisms by which LAR inhibition can affect respiratory neural cir
cuitry. Going forward, it will be important to test the combination of
LAR peptide with other strategies targeting axon growth inhibitory and
promoting mechanisms, as well as interventions such as rehabilitative
training regimens (Fuller and Mitchell, 2017), to promote additive – or
even synergistic – therapeutic effects on respiratory function following
SCI.

3.4. Immune cell response
Development and function of the immune system is regulated by
RPTPs such as LAR and PTPσ (Pike and Tremblay, 2013). Furthermore,
intraspinal inflammatory cell responses after SCI affect axon growth
processes such as dieback and regrowth (Silver et al., 2014). Therefore,
it is possible that LAR peptide indirectly impacted rVRG and seroto
nergic axon growth via primary effects on inflammatory processes
within the lesion and in the surrounding intact spinal cord. Interestingly,
PTPσ genetic knockout or peptide-based inhibition worsen autoimmune
responses in a mouse model of multiple sclerosis (Ohtake et al., 2017),
suggesting that LAR inhibition could worsen outcome after cervical SCI
by magnifying the proinflammatory response and therefore not produce
the beneficial effects we observe in the current study. However, like
other biological processes regulated by proteoglycan signaling, the ef
fects of RPTP activation depend on the specific receptor (e.g. LAR versus
PTPσ effects can differ). In addition, the immune cell effects of signaling
can vary depending on whether the ligand is CSPG or another proteo
glycan such as HSPG that can produce in some cases drastically different
biological outcomes (Ohtake et al., 2018). Relative to PTPσ, little is
known about the role of LAR in immune cell function (Kondo et al.,
2010; Terszowski et al., 2001), particularly in the context of nervous
system pathophysiology. Future work will be needed to explore the
contribution of immune cell modulation to LAR peptide effects after SCI.
3.5. Source of CSPGs acting on LAR

3.7. Experimental procedures

Findings in the field are beginning to suggest that a major portion of
the axon growth- inhibitory CSPGs is not provided by reactive astrocytes
around the lesion, but instead by non-astrocyte sources such as other
scar-forming cell types (Anderson et al., 2016; Cregg et al., 2014).
Importantly, an ongoing body of work (Smith et al., 1986; Smith et al.,
1987; Smith et al., 1990; Smith and Silver, 1988), including exciting
recent studies (Anderson et al., 2016), suggests that astrocytes are axon
growth-promoting, contrary to long-established beliefs. Astrocytemediated mechanisms that may be capable of promoting regeneration
of damaged axons and sprouting of spared fibers include: (1) providing a
cellular substrate for axon extension in the cystic lesion; (2) provision of
beneficial molecules such as neurotrophins (Davies et al., 2006; Haas
et al., 2012; Hamby and Sofroniew, 2010; Hill et al., 2004); (3) pro
duction of extracellular matrix and cell adhesion molecules (Falnikar
et al., 2015); and (4) immunomodulation (Sofroniew, 2015). Further
more, therapeutic approaches aimed at enhancing the presence of proregenerative astrocytes using strategies such as transplantation of
astrocyte progenitors or differentiated astrocytes have shown success in
promoting axon growth in animal models of CNS trauma, including SCI
(Davies et al., 2006; Davies et al., 2008; Haas and Fischer, 2013; Haas
et al., 2012; Shih et al., 2014; Smith et al., 1986; Smith et al., 1987;
Smith et al., 1990; Smith and Silver, 1988).

3.7.1. Animals
Adult female Sprague-Dawley rats weighing 250–350 g from
ENVIGO (formally Harlan Laboratories) were used in this study. Male
animals were not used in this study. Rats were housed in a controlled
environment (12 h light/dark cycles) with food and water ad libitum. All
experimental procedures involving animals were performed under the
approval of the Institutional Animal Care and Use Committee (IACUC) of
the Thomas Jefferson University. Animal surgeries and pre- and postsurgical care were performed in compliance with ARRIVE (Animal
Research: Reporting of In Vivo Experiments) Guidelines for the Care and
Use of Laboratory Animals. Prior to surgery, animals were randomly
assigned into the following groups: DMSO-only vehicle control or LAR
peptide. All surgeries and subsequent functional and histological ana
lyses were always performed in a blinded manner. DMSO-only treated
animals served as vehicle controls and were subjected to the same
procedures as the LAR peptide animals, with the only exception that the
LAR peptide was not administered.
3.7.2. Spinal cord injury (SCI) and postoperative care
Anesthesia was induced with xylazine (10 mg/kg, s.q.) (Akorn Inc.,
Lake Forest, Illinois) and ketamine (120 mg/kg, i.p.) (Vedco, Saint Jo
seph, Missouri). The skin overlying the dorsal side of spinal cord was
shaved and disinfected (betadine and 70% ethanol wipes) before sur
gery. A midline longitudinal incision was made from the base of the skull
to the shoulder blades through the skin and muscle overlying the cer
vical vertebrae. A laminectomy was performed to expose the C2 spinal
cord and a right C2 hemisection was performed caudal to the C2 rootlets
from the midline to lateral edge of the spinal cord using a micro-scalpel
(Urban et al., 2018). To ensure a complete hemisection, a 30-gauge
needle (BD Biosciences, San Jose, California) was passed through the
lesion several times. Following complete hemisection, the overlying
muscles were sutured with sterile 4–0 Vicryl suture, and the skin was
closed with sterile wound clips (Braintree Scientific, Braintree, Massa
chusetts). Rats were given antisedan (1.2 mg/kg, s.q.) (Zoetis,
Parsippany-Troy Hills, New Jersey), lactated Ringer’s solution (10 ml, s.
q.) and buprenorphine (0.01 mg/kg, s.q.) (Patterson Veterinary,

3.6. Conclusions and future directions
Excitingly, we have shown that inhibition of LAR via a peptide-based
approach results in significant recovery of diaphragm function, rela
tively long-distance regeneration of descending respiratory axon pop
ulations and partial reconnection of damaged rVRG-PhMN-diaphragm
circuitry in a severe model of high-cervical SCI. Moving forward, it will
be important to extend this work to test delivery at a more delayed time
point post-injury, including in a chronic SCI model given the large
population of individuals that are chronically injured (Ahuja et al.,
2017). In this study, we employed a relatively-invasive peptide delivery
approach involving surgical placement of the soaked gelfoam on the
dorsal surface of the spinal cord. It will be critical to determine whether
we can also achieve similar therapeutic efficacy with less-invasive
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Greeley, Colorado) immediately after surgery. Rats were then placed in
a clean cage on a surgical heating pad set to 37 ◦ C (Gaymar, Orchard
Park, New York) continuously for 5 days. Lactated Ringer’s solution (30
ml/day, s.q.) and oral Nutri-cal supplements (1–3 ml/day, Vetoquinol
USA Inc., Fort Worth, Texas) were provided until adequate normal
eating and drinking resumed. Signs of pain/distress, respiratory distress
and infections were closely monitored postoperatively.

Choleragenoid) from Vibrio cholera (List Biological Labs). Injections
were performed transcutaneously into the intrapleural space on each
side (5–7 mm deep, from skin). Animals were monitored closely for any
signs of respiratory deficits such as that following unintentional pneu
mothorax, but none were evident in all animals in this study.
3.7.6. Electromyography (EMG) recordings and analysis
All animals were anesthetized with xylazine (10 mg/kg, s.q.) and
ketamine (120 mg/kg, i.p.). The skin overlying the abdomen was
shaved, and an incision was made to expose the right and left hemi
diaphragm. Bipolar electrodes spaced 3 mm apart were placed for
recording in three separate sub-regions of the hemidiaphragm: dorsal,
medial, and ventral. EMG activity (10,000 samples/s) was amplified and
filtered through a band-pass filter (50–3000 Hz) by using a PowerLab 8/
30 data acquisition system (AD Instruments, Colorado Springs, Colo
rado) (Li et al., 2015a). Recordings were made separately in each subregion from each animal. Diaphragm EMG traces were rectified and
integrated (time constant decay 0.05 s) using LabChart 7 software (AD
Instruments, Colorado Springs, Colorado). For each muscle sub-region in
an animal, diaphragm output was determined by averaging integrated
signal across all inspiratory bursts from three 30-s intervals (30-s in
tervals were selected that had no sighs) over the total five-minute
recording time.

3.7.3. LAR peptide treatment
LAR peptide was synthesized commercially with C-terminal amida
tion by CHI Scientific, and peptide purity was analyzed by mass spec
trometry. The peptide sequence was published previously (Fisher et al.,
2011). Lyophilized peptide was dissolved in DMSO and then diluted to
the final concentration (15 mg/ml) in sterile calcium-free Hanks’
balanced salt solution. LAR peptide or DMSO-only vehicle were soaked
in gel foam (3.0 mm length x 3.0 mm width x 2.5 mm depth in size) and
placed directly over the lesioned spinal cord (50 μl/rat), both immedi
ately after hemisection and again at 7 days post-injury. With respect to
the experimental design of peptide delivery, we based this on both our
preliminary experiments and practical considerations. However, it is
important to point out that it is impossible to identify the perfect de
livery paradigm. We choose to deliver the peptide with the soaked
gelfoam approach, and we replaced the gelfoam with a fresh piece of
soaked gelfoam only once at 7 days post-injury. We chose not to replace
the gelfoam additional times for more prolonged delivery because each
replacement involves an invasive spinal surgery. Therefore, our para
digm was a balance of practicality and maximizing duration and dosing
of delivery. We have shown that delivery of PTPσ peptide with this same
gelfoam method promotes significant recovery of diaphragm function in
C2 hemisection SCI rats (Urban et al., 2020). We waited until 8 weeks
post-injury to perform functional analysis and to sacrifice the animals to
provide sufficient time for axon growth and synaptic connectivity. A
number of studies reported that SCI rodents maintain functional re
covery after terminating peptide-based treatments that promote axon
growth (Fisher et al., 2011; Lang et al., 2015; Li and Strittmatter, 2003).
It is possible that we would observe similar functional and histological
efficacy if animals were sacrificed at an earlier time point; however, we
chose only the later time point for this study.

3.7.7. Compound muscle action potential (CMAP) recordings
Phrenic nerve stimulation and CMAP recordings were performed
with ADI Powerlab 8/30stimulator and BioAMPamplifier (ADInstru
ments) (Li et al., 2015b). Rats were anesthetized with isoflurane (Pira
mal Healthcare, Bethlehem, Pennsylvania) at a concentration of
2.5–3.0% diluted in oxygen. Rats lay supine and a ground electrode was
placed subcutaneously into tail. Recording was obtained from the uni
lateral costal margin via standard surface electrode. The reference
electrode was placed subcutaneously into the contralateral lower
abdominal region. The single stimulus duration was set to 0.5 millisec
onds duration at 6 mV (amplitude). Stimulating electrodes were placed
transcutaneously approximately 1.0 cm deep, 0.5 cm apart, lateral to the
trachea and superior to the clavicle. After the single supramaximal
stimulation, repetitive nerve stimulation (~ 10 times), with the
recording and stimulating electrodes in the same positions, was applied
to obtain the average response. A supramaximal CMAP was obtained,
and the amplitude was measured from baseline to peak.

3.7.4. Rostral ventral respiratory group (rVRG) injection
We used adeno associated virus (AAV) serotype 2 driving expression
of red fluorescent protein (AAV2-mCherry) to examine the distribution
of bulbospinal rVRG projections to the phrenic motor nucleus (Urban
et al., 2018). Rats were anesthetized with a mixture of ketamine/xyla
zine. The head of each rat was fixed in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA) with the mouthpiece set at − 11 mm below
the interaural line. The atlanto-occipital membrane was incised, and the
lower aspect of the occipital plate was removed to allow penetration of
the injection needle. Focal pressure injections of AAV2-mCherry (me
dulla; titer: 1.66 × 10e13 vg/ml; volume: 0.3 μl controlled by Micro4
Microsyringe Pump) were targeted to the medullary rVRG located at the
following coordinates: 2.0 mm lateral, 1.0 mm rostral, and 2.6 mm
ventral from calamus scriptorius, as determined in separate neuro
physiological findings (Bezdudnaya et al., 2017; Zheng et al., 1998). In
animals receiving C2 hemisection, brainstem and spinal cord tissues
were harvested 4 weeks following AAV injection.

3.7.8. Diaphragm whole-mount histological neuromuscular junction (NMJ)
analysis
For microscopic examination of whole-mount diaphragm, the dia
phragm was dissected, rinsed in PBS (pH 7.4) and fixed in 4% para
formaldehyde (PFA) in PBS at room temperature for 20 min. After the
removal of connective tissue, the whole-mount diaphragm was incu
bated in 0.1 M glycine for 30 min at room temperature. The postsynaptic nicotinic acetylcholine receptors in the diaphragm were
labeled with α-Bungarotoxin, Alexa Fluor 555 conjugate (1:200, Invi
trogen) at room temperature for 15 min. After washing, the wholemount diaphragm was permeabilized with ice-cold methanol for 5
min, and then were blocked for 1 h at room temperature in a TritionBSA-PBS solution composed of 2% bovine serum albumin and 0.2%
Triton X-100 diluted in PBS. The diaphragms were incubated with presynaptic vesicle marker anti-SV2 antibody (1:10, Developmental
Studies Hybridoma Bank) and neurofilament marker anti-SMI-312
antibody (1:1000, Covance) at 4 ◦ C overnight. After washing with TBP
solution, the diaphragms were incubated with Fluorescein (FITC) Affi
niPure IgG, Fcγ subclass 1 specific secondary antibody (Jackson
ImmunoResearch Laboratories) for 1 h at room temperature. Di
aphragms were mounted with Vectashield mounting medium (Vector
Laboratories), coverslipped and stored at − 20 ◦ C. Two blinded re
searchers quantified the whole-mount diaphragms under a Leica fluo
rescence microscope. Total numbers of NMJs and percentages of intact,

3.7.5. Retrograde labeling of phrenic motor neurons (PhMNs)
PhMNs were retrogradely and bilaterally labeled 3 days prior to
tissue harvest (Li et al., 2014). Animals were induced with 3% isoflurane
in 100% O2, and rats were transferred to a pad and anesthesia was
maintained through a nose cone with 1.5–2% isoflurane. While stabi
lizing the animal’s back, the rib cage was palpated in order to identify
the fifth intercostal space at the anterior axillary line. Using sterile
conditions and appropriate antisepsis, a 50-μl Hamilton syringe was
used to inject 15–20 μl of a 0.25% Cholera Toxin B Subunit (CTB,
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partially-denervated or completely denervated NMJs were analyzed
(Wright et al., 2009; Wright and Son, 2007). We morphologically eval
uated NMJ innervation by quantifying five different NMJ phenotypes at
individual synapses. For each hemidiaphragm/animal, we quantified
200–300 NMJs across the entire hemidiaphragm, and we expressed the
data for each NMJ phenotype as the percentage of total NMJs. We
performed this analysis on 3–4 animals per group. Each individual an
imal is represented by a separate circle or triangle in Fig. 3M. We con
ducted this NMJ morphological analysis to confirm that there was no
diaphragm denervation that could have resulted from factors such as
PhMN damage or even PhMN death, as well as to show that LAR peptide
administration did not impact diaphragm innervation by PhMNs.

formed a defined boundary between GFAP-positive and GFAP-negative
locations. Lesion borders were outlined manually based on images
taken with a 20× objective lens. In each quantified sagittal section,
rostral-caudal distance between the rostral and caudal lesion borders
was measured at three locations (i.e. at dorsal, medial and rostral por
tions of the lesion in the sagittal section) using the NIH ImageJ analysis
software, and three sections were averaged within an individual animal.
3.7.13. Spinal cord cresyl violet staining
40 μm transverse spinal cord sections were retrieved from the − 20 ◦ C
freezer and dried at room temperature overnight. Slides were then
dipped in dH2O for 30 s. Slides were next placed into a cresyl violet
solution (0.4% cresyl violet, 6% 1 M sodium acetate, 34% 1 M acetic
acid) for 18 min. Finally, slides were placed in baths of dH2O, 70%
ethanol, 95% ethanol, 100% ethanol and xylene. Slides were then
mounted with poly-mount xylene (Polysciences, Warrington, Pennsyl
vania) and coverslips were added. Slides were then kept at room tem
perature for analysis.

3.7.9. Spinal cord and brainstem dissection
Rats were euthanized with Euthasol. After the diaphragms were
excised, animals were perfused transcardially 8 weeks after injury with
saline, followed by cold 4% paraformaldehyde. After post-fixation in the
same fixative overnight, tissues were washed with 1xPBS and trans
ferred to 30% sucrose solution in 1xPBS.

3.7.14. Analysis of rVRG axon regeneration and sprouting
To visualize rVRG axons in animals with either ipsilateral or
contralateral injections of AAV2-mCherry into the rVRG, sagittal sec
tions were enhanced with a rabbit Living Colors DsRed Polyclonal
antibody 1:500 (Takara Bio Company) and an Alexa-594-conjugated
secondary antibody. For mCherry-labeled axon regeneration quantifi
cation (i.e. in rats injected with mCherry into ipsilateral rVRG), in the
sagittal sections of cervical spinal cord containing the lesion site, the
average number of mCherry-labeled axons that traversed through
various distances were counted at the lesion site and in intact rostral and
caudal spinal cord, using rostral lesion-intact border as the distance
starting point (Urban et al., 2019b). For this rVRG axon regeneration
quantification, we counted numbers of rVRG axon profiles that crossed a
straight line (running from the dorsal to ventral part of the section)
placed at each of the rostral-caudal distances presented in the graph in
Fig. 5H. The same mCherry+ axon could be counted at multiple dis
tances (or even at the same distance because of branching and/or uturns). With this quantification, we are counting numbers of axon pro
files at various rostral-caudal distances to assess density of rVRG axon
growth.
For quantification of rVRG axon sprouting within the PhMN pool (i.e.
in animals injected with AAV2-mCherry into contralateral rVRG), we
quantified axon profile numbers within a constant-area size box (500
μm × 500 μm) at the location of CTB-labeled PhMNs on the side of C2
hemisection. Numbers of mCherry-labeled rVRG axons were obtained
and averaged separately at C3, C4 and C5 regions of spinal cord: +1.5
(mm), +3.0 (mm), and + 4.5 (mm), respectively (Urban et al., 2019b).
4–5 sections were analyzed per rat, and 4–5 rats per group were quan
tified. Similar to rVRG axon regeneration analysis described above, the
same rVRG axon could be counted more than once in this area box
because of branching and/or because the axon exited and re-entered the
40 μm tissue section in the z-plane and/or x-y plane.
For both rVRG axon regeneration and rVRG axon sprouting, we
present results as axon profiles. We identified an axon profile quanti
tatively as a continuous segment of mCherry-labeled axon that measures
at least 10 μm in length.

3.7.10. Immunohistochemistry
Spinal cord tissue extending from 10 mm rostral to the lesion to 10
mm caudal to the lesion (20 mm long, containing lesion area) was
embedded in OCT and cryosectioned parasagittally on a Microm HM550
cryostat Microtome (Thermo Scientific) (40 μm thick). The free-floating
sections were blocked/permeabilized with a solution of 5% Normal Goat
Serum (Vector Laboratories, Burlingame, California), 0.2% Triton X-100
(Amresco, Solon, Ohio), diluted in PBS (primary and secondary anti
bodies were diluted in this solution as well) for 1 h at room temperature
and then processed with primary antibodies at 4 ◦ C overnight using
procedures for immunocytochemistry, as described previously. Multiple
primary antibodies were used in combination, including rabbit glial
fibrillary acidic protein (GFAP) (1:500, RRID: AB_10013382, Dako),
rabbit-anti-dsRed (1:500, Living Colors DsRed pAb, RRID: AB
_10013483; Takara Bio USA, Mountain View, CA, USA) to enhance
mCherry fluorescence, goat-anti-CTB (1:10,000; RRID: AB_10013220;
List Biological Laboratories), mouse-anti-vesicular glutamate trans
porter 2 (1:250, RRID: AB_2187552; MilliporeSigma), rabbit-anti-5hydroxy-tryptamine (5-HT; 1:15,000, RRID: AB_572263; ImmunoStar,
Hudson, WI, USA). All secondary antibodies were used at 1:200 dilution
for 1 h at room temperature and included: Alexa Fluor 647 AffiniPure
Donkey anti-mouse, Alexa Fluor 488 AffiniPure donkey anti-goat, Alexa
Fluor 647-conjugated donkey anti-goat, Alexa Fluor 488 AffiniPure
donkey anti-rabbit (Jackson Immuno-Research Laboratories), and Alexa
Fluor 594-conjugated donkey anti-rabbit (Abcam, Cambridge, MA,
USA). The sections were mounted, dehydrated, covered with Fluo
rSave™ Reagent (Millipore) and then added with cover slips. Stained
sections were examined using a Leica SP8 confocal microscope (Leica
Microsystems Inc., Buffalo Grove, IL). Image analysis was performed
using Image J (NIH), as described previously (Urban et al., 2019a).
3.7.11. Counts of transduced rVRG neurons
To quantify numbers of AAV-mCherry transduced rVRG neuron cell
bodies, 40 μm transverse sections of the medulla were imaged with a
Zeiss Axio M2 Imager (Carl Zeiss Inc.). Images were then optically
“stitched” by MetaMorph software (Molecular Devices; RRID:
SCR_002368) to generate a complete image of the entire medulla sec
tion. The number of mCherry+ transduced neurons in the rVRG per
section were counted and averaged over multiple sections to obtain a
single value for each animal.

3.7.15. Analysis of putative rVRG-PhMN monosynaptic connections
To quantify putative monosynaptic connections between presynaptic mCherry+/Vesicular Glutamate Transporter 2 (VGLUT2)+
rVRG axon terminals and post-synaptic CTB+ PhMNs, longitudinal sec
tions were triple immunostained with antibodies directed against Living
Colors DsRed, VGLUT2 (Sigma) and Cholera Toxin B Subunit (List Bio
logical Laboratories). For quantification of the number of putative
monosynaptic connections at C3, C4 and C5 regions ipsilateral to the
lesion, mCherry/VGLUT2 double-positive signals directly pre-synaptic
to the somata of CTB+ PhMNs were identified under orthogonal view

3.7.12. Lesion size measurement
Lesion edge was defined as the interface between the GFAP-negative
and GFAP-positive regions surrounding the lesion core. GFAP-negative
tissue was defined as tissue that had little GFAP immunoreactivity,
with few GFAP-positive cells or processes. GFAP-positive processes
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in single-z confocal images (Urban et al., 2019b). We confirmed overlay
of the VGLUT2 and mCherry signals in both the x-y and z planes. Using
the same approach, we also quantified numbers of putative mCherry− /
VGlut2+ excitatory synapses onto CTB+ PhMNs (from non-rVRG excit
atory neurons) at C3 on the side of hemisection.
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3.7.16. Analysis of serotonergic axons
For serotonin axon labeling, parasagittal sections were immuno
stained with a rabbit anti-5-HT antibody (ImmunoStar) and Alexa-488conjugated secondary antibody. For serotonergic axon quantification,
the individual fibers stained by 5-HT antibody within a constant-area
size box (500 μm × 500 μm) at the location of CTB-labeled PhMNs at
C3, C4 and C5 regions were traced and the total length of all traced 5-HT
axons was calculated from two random sections in each rat. Specifically,
this sprouting quantification was performed within the ipsilateral PhMN
pool on the side of C2 hemisection (Urban et al., 2019a).
3.7.17. Statistical analysis
All data are presented as the mean ± SEM. OriginPro 8.0 (OriginLab
Corp.) was used for all statistical analysis. Data were analyzed with a
one-way analysis of variance followed by a Tukey’s multiple comparison
test or a two-tailed Student’s t-test. Pearson Correlation was used to
examine correlation. P value <0.05 was considered significant.
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